Enthesitis-Related Arthritis
Enthesitis-Related Arthritis
This category covers treatments and supplies used for Enthesitis-Related Arthritis (ERA), a subtype of juvenile idiopathic arthritis, where inflammation occurs at tendon and ligament attachment sites called entheses; typical issues include heel pain, morning stiffness, and joint swelling, and care teams may consider imaging findings and lab markers when planning therapy and monitoring response. You can compare biologic injectables, autoinjector pens, prefilled syringes, and supportive accessories by brand, form, and strength, review dosing ranges across pediatric and adult care, and see class-level safety notes; availability can vary by batch, and listings may change, with US shipping from Canada depending on inventory and applicable regulations. Use this page to scan options by mechanism, dosing frequency, and administration technique, review clinical class information paired with plain-language explanations, and connect to related conditions so you can navigate quickly to product pages or condition guides without guesswork.What’s in This CategoryThis category groups biologic disease-modifying agents, non-biologic DMARDs, and injection supplies commonly used in ERA and overlapping spondyloarthritis. Options include interleukin-17 inhibitors, tumor necrosis factor inhibitors, and agents affecting IL-12/23 pathways. Listings may also include alcohol swabs, pen needles, and sharps containers for safe disposal. Common enthesitis-related arthritis symptoms involve localized tendon insertion pain, activity-related flares, and stiffness after rest. For axial symptoms or sacroiliac pain, clinicians may align choices with spondyloarthritis practice patterns.Forms include prefilled syringes and autoinjector pens designed for subcutaneous use. Cold-chain handling with insulated packaging and refrigerant packs is typically required for biologics. Radiology can support assessment; ultrasound can show power Doppler signals at the enthesis, and MRI for enthesitis helps detect bone marrow edema or soft-tissue inflammation. When axial features are prominent, compare resources for Ankylosing Spondylitis and pediatric pathways within Juvenile Idiopathic Arthritis. To understand axial involvement further, see the overview article What Is Ankylosing Spondylitis.How to Choose: Enthesitis-Related ArthritisSelection usually considers disease activity, prior response, comorbidities, vaccination status, and patient age. Clinicians may use classification or diagnostic criteria to frame decisions, while also weighing growth considerations and school schedules for adolescents. If peripheral enthesitis predominates, an interleukin-17 pathway may be considered; if broader joint disease exists, a TNF inhibitor may fit goals. For overlapping features with Rheumatoid Arthritis or Psoriatic Arthritis, cross-condition evidence can help guide a plan. If insurance coding matters, teams may reference the ICD-10 code for ERA without changing clinical intent.Compare dosing intervals, device training needs, and monitoring plans. Autoinjector pens can help with needle aversion, while prefilled syringes offer control over injection speed. Check refrigeration requirements and travel storage time. Review radiology considerations if sacroiliac joints or heels are involved, and align follow-up intervals with symptom variability. Common mistakes to avoid include:Skipping education on device priming and site rotation.Overlooking refrigeration time needed before injection for comfort.Missing coordination of lab monitoring or vaccination timing.Popular OptionsCosentyx (secukinumab) targets IL-17A and is used across spondyloarthritis and plaque psoriasis. Subcutaneous forms include autoinjector and prefilled syringe presentations with maintenance dosing after a loading phase. Some prescribers select it as part of enthesitis-related arthritis treatment when ERA shows active enthesitis or axial features, aligning with evidence used in related conditions.Taltz (ixekizumab) is another IL-17A inhibitor with options for autoinjector use. It is considered where enthesitis drives disability, particularly with heel or plantar fascia involvement. Device training focuses on site selection and warming time outside the refrigerator before use. Teams often compare IL-17 options on dosing schedules, device comfort, and patient-reported outcomes.TNF inhibitors remain important choices across spondyloarthritis and juvenile categories. To understand comparative considerations around dosing, device formats, and age approvals, review the article Humira vs Enbrel. Other class members such as ustekinumab are sometimes discussed when psoriatic skin disease coexists or prior biologics have been inadequate, with selection guided by clinical response history and safety monitoring.Related Conditions & UsesEnthesitis occurs across the spondyloarthritis spectrum, including psoriatic disease and axial involvement. When skin plaques, nail changes, or dactylitis accompany tendon insertion pain, teams may consider psoriatic pathways and dermatology input. For broader joint pain across age groups, see the category overview for Arthritis. If skin and joint symptoms co-occur, the article Psoriatic Arthritis Symptoms explains typical patterns and when to escalate care.In pediatrics, juvenile idiopathic arthritis includes an enthesitis-related subtype with potential axial features and occasional uveitis risk. Management can overlap with adult spondyloarthritis when adolescents transition to adult services. For differential questions involving swelling patterns, consult the explainer Rheumatoid Arthritis vs Osteoarthritis to understand how imaging and serology differ. If care teams need historical context for imaging, JIA radiology discussions commonly address sacroiliac MRI protocols and heel-focused ultrasound techniques to document enthesitis.Medical disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice.Authoritative SourcesFor pediatric classification and family guidance, see the American College of Rheumatology overview for JIA patients on its patient education page.For biologic class safety, the FDA drug safety and availability resource provides neutral summaries on postmarket safety communications.For biologics and biosimilars background, Health Canada describes regulatory principles and monitoring; this can help frame enthesitis related arthritis hla-b27 context in practice on its biologics page.
Filter
Product price
Product categories
Conditions
Select options
This product has multiple variants. The options may be chosen on the product page
Frequently Asked Questions
How do I choose between pens and prefilled syringes?
Start with device training needs and comfort. Pens can help with needle aversion and one-button activation. Prefilled syringes offer control over injection speed and allow caregivers to supervise technique closely. Check dosing schedules, because some products offer both devices while others do not. Confirm refrigeration, in-use times at room temperature, and travel storage limits. Review device-specific instructions in the product’s official patient information before selecting a format.
Are cold-chain biologics handled safely during delivery?
Yes, shipments typically use insulated packaging and refrigerant packs. Carriers and warehouses aim to maintain recommended temperature ranges from dispatch to delivery. Open the parcel promptly, verify contents and temperature indicators if provided, and store items in the refrigerator as directed. Avoid freezing. If a delay or warm package occurs, follow the product’s handling guidance and contact the dispensing pharmacy or your care team for stability advice.
Do I need a prescription for medicines listed here?
Most biologic agents require a valid prescription. Requirements can vary by jurisdiction, product, and patient age, and listings may reflect different package sizes or devices. Check local regulations and your prescriber’s plan before ordering. Some items, like alcohol swabs or sharps containers, may be available without a prescription. Always follow your clinician’s directions regarding dosing, lab monitoring, and vaccinations.
What if a product is out of stock when I browse?
Inventory can change due to manufacturing schedules, shipping timelines, or demand. If an item shows as unavailable, consider alternate strengths, devices, or a therapeutically similar class member. Your care team can advise on staying within the treatment plan. You can also review related categories on the site to identify comparable mechanisms or dosing schedules that meet your clinical requirements.
Can adults use options listed for juvenile disease?
Some products have indications across both pediatric and adult spondyloarthritis, while others are age-restricted. Adult dosing, safety considerations, and monitoring can differ from pediatric protocols. Confirm the label indication, age approvals, and any bridging guidance when transitioning adolescents. Review class safety information and discuss the plan with your clinician to ensure continuity and appropriate monitoring during any change in care.
Related Articles
Pain & Inflammation
Arthritis Awareness Month: Juvenile Arthritis Facts and Support
Key TakeawaysEarly recognition helps prevent joint damage and disability.Colors and symbols unify campaigns and drive visibility.Events create structure for education, advocacy, and fundraising.Treatment plans mix medicines, movement, and monitoring.Families and…